Burke & Burke
Financials
Estimates*
EUR | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|---|
Revenues | 16.7m | 19.6m | 43.6m | 24.9m | 24.2m | 39.3m |
% growth | - | 17 % | 122 % | (43 %) | (3 %) | 63 % |
EBITDA | 2.0m | 3.4m | 12.5m | 6.0m | 6.3m | - |
% EBITDA margin | 12 % | 17 % | 29 % | 24 % | 26 % | - |
Profit | 1.0m | 2.0m | 8.6m | 3.9m | 1.9m | - |
% profit margin | 6 % | 10 % | 20 % | 16 % | 8 % | - |
Date | Investors | Amount | Round |
---|---|---|---|
* | N/A | Growth Equity VC | |
* | N/A | Acquisition | |
Total Funding | - |
Recent News about Burke & Burke
EditBurke Burke specializes in providing advanced medical solutions for neonatal and critical care. The company offers a range of innovative products and customized clinical support to ensure the highest level of care in neonatal intensive care units, delivery rooms, and during transport. Their product lines include warming therapy systems to create safe and controlled environments for newborns, neurology and neuroprotection solutions for monitoring and treating neurological damage at birth, and hearing screening systems for early detection of deafness in neonates. Additionally, Burke Burke provides reliable anesthesia systems for various surgical settings, comprehensive jaundice management solutions, and a range of oxygen therapy products designed to meet diverse clinical needs. The company serves healthcare providers and medical institutions, operating in the medical devices market. Burke Burke's business model focuses on selling high-quality medical equipment and offering ongoing service support to ensure optimal performance and patient outcomes.
Keywords: neonatal care, critical care, warming therapy, neuroprotection, anesthesia systems, jaundice management, oxygen therapy, medical devices, clinical support, healthcare providers.